Gilead next earnings
WebApr 14, 2024 · Gilead Sciences, Inc. has a 52 week low of $57.17 and a 52 week high of $89.74. Gilead Sciences ( NASDAQ:GILD – Get Rating) last released its quarterly earnings data on Thursday, February 2nd. The biopharmaceutical company reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.17. WebAt Gilead, we promise to treat your data with respect. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.
Gilead next earnings
Did you know?
WebApr 6, 2024 · This reflects a positive earnings surprise of 11.33%. Look out for GILD's next earnings release expected on April 27, 2024. For the next earning release, we expect … WebApr 13, 2024 · This has lagged the Medical sector's gain of 6.85% and the S&P 500's gain of 6.51% in that time.Gilead Sciences will be looking to display strength as it nears its next earnings release. On that ...
Web2 days ago · Gilead reported oncology therapy sales of $2.1 billion in 2024, up 71%. Its lead oncology drug, personalized cell therapy Yescarta, is used to treat large B-cell lymphoma … WebFeb 2, 2024 · Feb 2, 2024 4:30 PM ET. Webcast. Q4 2024 Earnings Release. Q4 2024 Presentation. Q4 2024 Supplementary Information. Q4 2024 Prepared Remarks. Q4 2024 Summary of Prepared Remarks. Q4 2024 Resource Book. Q4 2024 10-K.
WebOct 29, 2024 · During the third quarter, adjusted Gilead earnings climbed 26% to $2.65 per share and crushed views for $1.76 a share. Sales were $7.42 billion, well above GILD stock analysts' call for $6.29 billion. WebApr 14, 2024 · Gilead Sciences (NASDAQ:GILD - Get Rating) last announced its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.17. The business had revenue of $7.39 billion for the quarter, compared to analyst …
WebJan 30, 2024 · For the most recent quarter, Gilead was expected to post earnings of $1.44 per share, but it reported $1.90 per share instead, representing a surprise of 31.94%. For …
WebFeb 2, 2024 · As of December 31, 2024, Gilead had $7.6 billion of cash, cash equivalents and marketable debt securities compared to $7.8 billion as of December 31, 2024. During the fourth quarter 2024, Gilead generated $2.6 billion in operating cash flow. During the fourth quarter 2024, Gilead paid cash dividends of $916 million and utilized $791 million … boots the chemist photo printingWebJan 30, 2024 · Gilead currently has an Earnings ESP of +6.63%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with... boots the chemist perth road dundeeWebApr 6, 2024 · Gilead Sciences, Inc. (GILD) latest earnings report: revenue, EPS, surprise, history, news and analysis. boots the chemist pharmacy deliveriesWebOct 27, 2024 · Webcast. Q3 2024 Earnings Release. Q3 2024 Presentation. Q3 2024 Supplementary Information. Q3 2024 Prepared Remarks. Q3 2024 Summary of Prepared Remarks. Q3 2024 Resource Book. Q3 2024 10-Q. boots the chemist pharmacy servicesWebAug 3, 2024 · Gilead’s cell therapy business outperformed Wall Street expectations during the second quarter. The unit — which currently consists of two products, Yescarta and Tecartus, used to treat various blood cancers — generated $368 million in the three-month period, an increase of 68% year over year, earnings numbers released Tuesday show. boots the chemist pewseyWebOn this page we presented the GILD Next Earnings Date information for Gilead Sciences along with recent past earnings dates. For Q4 of 2024, GILD reported earnings of 1.670/share, with the earnings report taking place on 2/2/2024. For Q3 of 2024, GILD reported earnings of 1.900/share, with the earnings report taking place on 10/27/2024. boots the chemist pickeringWebAug 2, 2024 · During the second quarter of 2024, Gilead generated $1.8 billion in operating cash flow. During the second quarter of 2024, Gilead made a $300 million collaboration upfront payment to Dragonfly, paid dividends of $920 million and repurchased $72 million of common stock. Product Sales Performance boots the chemist petts wood